{"id":764989,"date":"2023-06-21T07:03:37","date_gmt":"2023-06-21T11:03:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/"},"modified":"2023-06-21T07:03:37","modified_gmt":"2023-06-21T11:03:37","slug":"monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/","title":{"rendered":"Monopar to Participate in the Radiopharma Forum by the Lake 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WILMETTE, Ill., June  21, 2023  (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar\u2019s Chief Executive Officer, will participate in a panel discussion at the \u201cRadiopharma Forum by the Lake\u201d on Monday June 26, 2023, at 6:15pm CT at the Chicago Club.<\/p>\n<p>\u201cWe are excited to be a part of this event, which is bringing together leaders in the radiopharma space, from drug development companies to investors to isotope manufacturers to CDMO\u2019s. We intend to highlight our lead radiopharma program focused on the novel target uPAR along with a linker that binds to actinium-225 with high affinity which we filed a patent on,\u201d said Dr. Robinson.<\/p>\n<p>Due to favorable properties such as its long half-life, high potency, and short distance of activity, actinium-225 (Ac-225) is quickly emerging as a therapeutic isotope of choice. Monopar\u2019s filed patent relates to the novel finding that antibodies conjugated to the linker PCTA can achieve nearly 100% binding to Ac-225. The PCTA-antibody conjugates also appear to bind daughter ions, such as Bi-213, with high affinity. This high affinity binding may decrease the amount of Ac-225 and its daughter ions that permanently detach from the antibody, which could potentially reduce off-target toxicity and increase efficacy by enabling higher effective dosing.<\/p>\n<p>\n        <strong>About Monopar Therapeutics Inc.<\/strong>\n      <\/p>\n<p>Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar&#8217;s pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma\u037e MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers\u037e and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y-M7PolH5VRMhdJhlvGQySnFk42skD997xEsY1kcEjlOl0Eu7YSg811MJ-veCNhdPXOl2PcT9e78Bci5nREjXFdALnBNXG6EBMPTfja1p3SDqsMo5YnawUl3aUBYwhyrh9vxFcGoDTuJh6mcMr0vqlui24p3GK8MyYK6gGKKjfRqWHAnuBPVqhJaVWWYMyeKy7KvQYvSNERq1X3gQ3GSBDsFjEqglEKgpAdWUzSAzJ118MiwGWJ3CyaEww9jT8rYcGsOOHJDi_N4jpQpiSunjOyZYgTjVHf70ugSFrAFOHMLWQXjwV8U5w3XgtfcXvipTY2G0c4XJGoPiPopKeopI-MNwEp6jTeb_6EBI2h6srDvgRMjnv4SuWlKm94RTve7ry3cXbF6J8szfzG7iis3mmo8YDndD860Gb7Fm98k9Uw=\" rel=\"nofollow noopener\" target=\"_blank\">www.monopartx.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Statements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward\u00ad-looking statements include statements concerning: that actinium-225 (Ac-225) is quickly emerging as an isotope of choice; and that high affinity binding may decrease the amount of Ac-225 and its daughter ions that permanently detach from the antibody, which could potentially reduce off-target toxicity and increase efficacy by enabling higher effective dosing. The forward-looking statements involve risks and uncertainties including, but not limited to: Ac-225 bound to an antibody does not prove efficacious in preclinical and clinical studies; and the Company\u2019s inability to raise sufficient funds or engage a partner to continue the camsirubicin clinical program through and beyond the Phase 1b clinical trial and to further develop MNPR-101-Zr with its collaboration partner if its first-in-human trial is successful\u037e the effects of general economic and market conditions on Monopar\u2019s operations and ability to raise funds\u037e and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar&#8217;s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p>\n        <strong>Monopar Therapeutics Inc.<\/strong><br \/>\n        <br \/>Investor Relations<br \/>Kim R. Tsuchimoto<br \/>Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EVC4F1CKJrgzlUQiSdkhkiHUTcAaR_pVk8ROntapeAUz6EPsa_zHNdR1NiKWwS0OWmworGhMFNmwbRUK7dtJhGhzhcHxPiVqm9kXMpV8DyC8K6dP-9wrrSddvhdkafSNT0MFad-dATes7vLFOKtN2WqBIs4W7s1qysqGyfPN6lLuk7DFk1j2oYvZFC_MEg8C0v8gYUXIQPJ6GMzoPYF9eHWxA3chklVF2ePvzJgcms87ZPWlucq_sFXy3j48-XSC7Y_mnlB5l8GCfjhdX9kreg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>kimtsu@monopartx.com<\/u><\/a><\/p>\n<p>Follow Monopar on social media for updates:\u2009 <br \/>Twitter: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=37frlA6yWprx3zqVG-yEJEOYiB12mWZQydZL1qdeFG00tLLjUJNm-0PlqF-fvTJoD-m7sTIGhwTtZiDbGpwncGj5sA96ey9iTkjsuKIOMbUC9d6r-fip4uqIez_2FUuc7ekfQChMfeiFI_2eazA42I-X7n-KIHvwu4MtCZxB2mzW6KtxbEoCyJmXfuSEOHAgDPtmi4N9MTRJQPVscY6Fyw1RjXo1JlVySdtvO-NQb9U=\" rel=\"nofollow noopener\" target=\"_blank\"><u>@MonoparTx<\/u><\/a>\u2009\u00a0 LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Cjr_MCkCJDqnBiW-YODpOIXo7DnUpSeZMZJyvaEHjI74a1SgBSPuvUa6_VavYr1uMCiEfPrq84b5cx78Q82Wvq-7YADddZMF3Bahyet_zsmXeQZpDDluMEq7Yf4oY3qzKyk0codCjk79SHaby4ubRbzn6q7uWBxYtuYpq2nsCwLSdl8gbOkG7ru-ZrQ02hO0SlUkpwxlslc2zALWiSdQKNRCusH99sRt58ZgwisulRk4isAadsvBMIgk2amMsaFftONK7fdOlgOrhMO0dL5K5GrLw8E-ktgyhLpxW3Au2WjTer-bqlYtlSarmmqvWOMq\" rel=\"nofollow noopener\" target=\"_blank\"><u>Monopar Therapeutics<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmEyMjAzNTEtMjc5Ni00ZTE3LTliZDgtY2JlNmZhOWNjYjQ2LTEyMDU0MTY=\/tiny\/Monopar-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar\u2019s Chief Executive Officer, will participate in a panel discussion at the \u201cRadiopharma Forum by the Lake\u201d on Monday June 26, 2023, at 6:15pm CT at the Chicago Club. \u201cWe are excited to be a part of this event, which is bringing together leaders in the radiopharma space, from drug development companies to investors to isotope manufacturers to CDMO\u2019s. We intend to highlight our lead radiopharma program focused on the novel target uPAR along with a linker that binds to actinium-225 with high affinity which we filed a patent &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monopar to Participate in the Radiopharma Forum by the Lake 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-764989","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monopar to Participate in the Radiopharma Forum by the Lake 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monopar to Participate in the Radiopharma Forum by the Lake 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar\u2019s Chief Executive Officer, will participate in a panel discussion at the \u201cRadiopharma Forum by the Lake\u201d on Monday June 26, 2023, at 6:15pm CT at the Chicago Club. \u201cWe are excited to be a part of this event, which is bringing together leaders in the radiopharma space, from drug development companies to investors to isotope manufacturers to CDMO\u2019s. We intend to highlight our lead radiopharma program focused on the novel target uPAR along with a linker that binds to actinium-225 with high affinity which we filed a patent &hellip; Continue reading &quot;Monopar to Participate in the Radiopharma Forum by the Lake 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-21T11:03:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monopar to Participate in the Radiopharma Forum by the Lake 2023\",\"datePublished\":\"2023-06-21T11:03:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/\"},\"wordCount\":644,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/\",\"name\":\"Monopar to Participate in the Radiopharma Forum by the Lake 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=\",\"datePublished\":\"2023-06-21T11:03:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monopar to Participate in the Radiopharma Forum by the Lake 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monopar to Participate in the Radiopharma Forum by the Lake 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/","og_locale":"en_US","og_type":"article","og_title":"Monopar to Participate in the Radiopharma Forum by the Lake 2023 - Market Newsdesk","og_description":"WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinson, MD, Monopar\u2019s Chief Executive Officer, will participate in a panel discussion at the \u201cRadiopharma Forum by the Lake\u201d on Monday June 26, 2023, at 6:15pm CT at the Chicago Club. \u201cWe are excited to be a part of this event, which is bringing together leaders in the radiopharma space, from drug development companies to investors to isotope manufacturers to CDMO\u2019s. We intend to highlight our lead radiopharma program focused on the novel target uPAR along with a linker that binds to actinium-225 with high affinity which we filed a patent &hellip; Continue reading \"Monopar to Participate in the Radiopharma Forum by the Lake 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-21T11:03:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monopar to Participate in the Radiopharma Forum by the Lake 2023","datePublished":"2023-06-21T11:03:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/"},"wordCount":644,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/","name":"Monopar to Participate in the Radiopharma Forum by the Lake 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=","datePublished":"2023-06-21T11:03:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MTc4NiM1NjU2NDYzIzIxOTM4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-participate-in-the-radiopharma-forum-by-the-lake-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monopar to Participate in the Radiopharma Forum by the Lake 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/764989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=764989"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/764989\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=764989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=764989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=764989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}